FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1608280314> ?p ?o ?g. }

• W1608280314 endingPage "684" @default.
• W1608280314 startingPage "676" @default.
• W1608280314 abstract "In the GLOBE trial, telbivudine demonstrated superior efficacy to lamivudine at 2 years in patients with chronic hepatitis B (CHB).To investigate the long-term efficacy and safety of telbivudine in the telbivudine-treated cohort from the GLOBE trial.Virological and biochemical responses were assessed in 213 HBeAg-positive and 186 HBeAg-negative CHB patients who continued telbivudine treatment for 3 years.Undetectable hepatitis B virus DNA and HBeAg seroconversions were achieved by 77 and 37% of HBeAg-positive patients respectively. Cumulative HBeAg seroconversion rate was 46%. HBeAg seroconversion was sustained at 52 weeks off therapy in 84% of the patients enrolled in the off-treatment follow-up arm of the study. Undetectable viraemia and normal alanine aminotransferase (ALT) levels at 3 years were achieved by 85 and 83% of HBeAg-negative patients respectively. Genotypic resistance rates for the study population who continued therapy during the third year were 11.3 in HBeAg-positive and 6.5% in HBeAg-negative patients. Patients with undetectable viraemia at treatment week 24 had optimal outcomes at 3 years. In the HBeAg-positive population, cumulative HBeAg seroconversion occurred in 58%. Resistance rates for HBeAg-positive and HBeAg-negative patients were 3.6 and 6.2% respectively. The telbivudine safety profile during prolonged therapy was similar to that in the GLOBE trial.Three years of telbivudine treatment yielded high rates of viral suppression and ALT normalization with a favourable safety profile. High rates of HBeAg seroconversion were achieved with prolonged telbivudine therapy and were sustained in the majority of patients over 52 weeks off therapy." @default.
• W1608280314 created "2016-06-24" @default.
• W1608280314 creator A5005792320 @default.
• W1608280314 creator A5006202942 @default.
• W1608280314 creator A5007668416 @default.
• W1608280314 creator A5008566878 @default.
• W1608280314 creator A5011767765 @default.
• W1608280314 creator A5014449655 @default.
• W1608280314 creator A5042155617 @default.
• W1608280314 creator A5042519419 @default.
• W1608280314 creator A5045392886 @default.
• W1608280314 creator A5050985880 @default.
• W1608280314 creator A5056241757 @default.
• W1608280314 creator A5059508363 @default.
• W1608280314 creator A5064143989 @default.
• W1608280314 creator A5072739378 @default.
• W1608280314 creator A5077186881 @default.
• W1608280314 creator A5088842832 @default.
• W1608280314 date "2011-03-16" @default.
• W1608280314 modified "2023-10-18" @default.
• W1608280314 title "Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B" @default.
• W1608280314 cites W133318803 @default.
• W1608280314 cites W1965962200 @default.
• W1608280314 cites W1976104517 @default.
• W1608280314 cites W1982812988 @default.
• W1608280314 cites W1984816914 @default.
• W1608280314 cites W1985860298 @default.
• W1608280314 cites W2004054613 @default.
• W1608280314 cites W2004100607 @default.
• W1608280314 cites W2009944703 @default.
• W1608280314 cites W2012405019 @default.
• W1608280314 cites W2017223730 @default.
• W1608280314 cites W2022770725 @default.
• W1608280314 cites W2027543203 @default.
• W1608280314 cites W2042284834 @default.
• W1608280314 cites W2049234248 @default.
• W1608280314 cites W2054772301 @default.
• W1608280314 cites W2055339444 @default.
• W1608280314 cites W2058376942 @default.
• W1608280314 cites W2064567106 @default.
• W1608280314 cites W2084713036 @default.
• W1608280314 cites W2094688618 @default.
• W1608280314 cites W2136425954 @default.
• W1608280314 cites W2140433311 @default.
• W1608280314 cites W2171150690 @default.
• W1608280314 cites W2314866596 @default.
• W1608280314 cites W2319441763 @default.
• W1608280314 doi "https://doi.org/10.1111/j.1478-3231.2011.02490.x" @default.
• W1608280314 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21457439" @default.
• W1608280314 hasPublicationYear "2011" @default.
• W1608280314 type Work @default.
• W1608280314 sameAs 1608280314 @default.
• W1608280314 citedByCount "40" @default.
• W1608280314 countsByYear W16082803142012 @default.
• W1608280314 countsByYear W16082803142013 @default.
• W1608280314 countsByYear W16082803142014 @default.
• W1608280314 countsByYear W16082803142015 @default.
• W1608280314 countsByYear W16082803142016 @default.
• W1608280314 countsByYear W16082803142017 @default.
• W1608280314 countsByYear W16082803142018 @default.
• W1608280314 countsByYear W16082803142020 @default.
• W1608280314 countsByYear W16082803142021 @default.
• W1608280314 crossrefType "journal-article" @default.
• W1608280314 hasAuthorship W1608280314A5005792320 @default.
• W1608280314 hasAuthorship W1608280314A5006202942 @default.
• W1608280314 hasAuthorship W1608280314A5007668416 @default.
• W1608280314 hasAuthorship W1608280314A5008566878 @default.
• W1608280314 hasAuthorship W1608280314A5011767765 @default.
• W1608280314 hasAuthorship W1608280314A5014449655 @default.
• W1608280314 hasAuthorship W1608280314A5042155617 @default.
• W1608280314 hasAuthorship W1608280314A5042519419 @default.
• W1608280314 hasAuthorship W1608280314A5045392886 @default.
• W1608280314 hasAuthorship W1608280314A5050985880 @default.
• W1608280314 hasAuthorship W1608280314A5056241757 @default.
• W1608280314 hasAuthorship W1608280314A5059508363 @default.
• W1608280314 hasAuthorship W1608280314A5064143989 @default.
• W1608280314 hasAuthorship W1608280314A5072739378 @default.
• W1608280314 hasAuthorship W1608280314A5077186881 @default.
• W1608280314 hasAuthorship W1608280314A5088842832 @default.
• W1608280314 hasConcept C126322002 @default.
• W1608280314 hasConcept C203014093 @default.
• W1608280314 hasConcept C2522874641 @default.
• W1608280314 hasConcept C2775940106 @default.
• W1608280314 hasConcept C2777410769 @default.
• W1608280314 hasConcept C2777451964 @default.
• W1608280314 hasConcept C2777869810 @default.
• W1608280314 hasConcept C2780593183 @default.
• W1608280314 hasConcept C2781144229 @default.
• W1608280314 hasConcept C2908647359 @default.
• W1608280314 hasConcept C3020491458 @default.
• W1608280314 hasConcept C71924100 @default.
• W1608280314 hasConcept C90924648 @default.
• W1608280314 hasConcept C99454951 @default.
• W1608280314 hasConceptScore W1608280314C126322002 @default.
• W1608280314 hasConceptScore W1608280314C203014093 @default.
• W1608280314 hasConceptScore W1608280314C2522874641 @default.
• W1608280314 hasConceptScore W1608280314C2775940106 @default.
• W1608280314 hasConceptScore W1608280314C2777410769 @default.

• next